Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amlodipine + desloratadine
- Development stage
- Unknown
- Lead developer
- Nabiqasim Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Am-Descol is a unique fixed-dose combination branded generic medication developed by Nabiqasim Industries, primarily marketed in Pakistan. It combines amlodipine, a long-acting dihydropyridine calcium channel blocker, with desloratadine, a non-sedating second-generation tricyclic antihistamine. Amlodipine acts by inhibiting the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and a reduction in blood pressure. Desloratadine is a selective peripheral H1-receptor antagonist used to manage symptoms of allergic rhinitis and urticaria. This combination is specifically designed for patients suffering from comorbid hypertension and allergic conditions, aiming to improve patient compliance by reducing the pill burden through a single-pill regimen.
- Brand names
- Am-Descol
- Other names
- amlodipine besylate + desloratadine
02
Targets
HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)CHRM4 (M4)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)HRH2 (Histamine H2 Receptor)CHRM5 (M5)CHRM2 (M2)
Beyond the preview
Go deeper on amlodipine + desloratadine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amlodipine + desloratadine.